{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:24:26Z","timestamp":1777983866608,"version":"3.51.4"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background\u2003International guidelines are increasingly recommending direct oral anticoagulants (DOACs) as the first-line treatment for cancer-associated thrombosis (CAT). However, data regarding treatment patterns and adherence to guidelines in patients with CAT are scarce.<\/jats:p>\n                  <jats:p>Objectives\u2003This study aimed to explore anticoagulant treatment patterns in patients with CAT and to calculate the incidence rates of bleeding events.<\/jats:p>\n                  <jats:p>Methods\u2003Patients \u226518 years with active cancer and a first-time venous thromboembolism between 2005 and 2020 were identified through the Venous Thrombosis Registry in \u00d8stfOLd HospitaL. Outcome measures were patterns of anticoagulant treatment during the study period and bleeding events. We calculated overall incidence rates per 100 person-years and 6- and 12-month cumulative incidence of major and clinically relevant nonmajor bleeding (CRNMB) during anticoagulant treatment.<\/jats:p>\n                  <jats:p>Results\u2003Median age of 842 CAT patients at the time of thrombosis was 69 years (interquartile range 61\u201377), and 443 (52.6%) were men. In total, 526 patients (62.5%) had pulmonary embolism and 255 (30.3%) had deep vein thrombosis. Low molecular weight heparin (LMWH) was prescribed to 713 (85.8%) patients, whereas 64 (7.7%) received DOACs and 54 (6.5%) received vitamin K antagonists as the initial anticoagulant treatment. Prescription of DOACs as initial treatment increased from 3.0% in 2013\/2014 to 18.0% in 2019\/2020. The incidence rate of major bleeding was 6.9 (95% confidence interval [CI] 5.2\u20139.2) and 10.1 (95% CI 8.0\u201312.9) in CRNMB.<\/jats:p>\n                  <jats:p>Conclusion\u2003Most patients were treated with LMWH. However, a gradual shift in treatment toward DOACs was observed. Overall, bleeding complications were rare and comparable to those reported in randomized trials.<\/jats:p>","DOI":"10.1055\/s-0044-1782219","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:05:35Z","timestamp":1711483535000},"page":"e132-e140","source":"Crossref","is-referenced-by-count":3,"title":["Real-world Data on Treatment Patterns and Bleeding in Cancer-associated Thrombosis: Data from the TROLL Registry"],"prefix":"10.1055","volume":"08","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5304-0666","authenticated-orcid":false,"given":"Zygimantas","family":"Zaboras","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla T\u00f8vik","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Emergency Medicine, \u00d8stfold Hospital, Sarpsborg, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Stensvold","sequence":"additional","affiliation":[{"name":"Department of Oncology, \u00d8stfold Hospital, Sarpsborg, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi Hassel","family":"Pettersen","sequence":"additional","affiliation":[{"name":"Department of Research, \u00d8stfold Hospital, Sarpsborg, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra Galovic","family":"Grdinic","sequence":"additional","affiliation":[{"name":"Clinic of Internal Medicine, \u00d8stfold Hospital, Sarpsborg, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrid Kufaas","family":"Br\u00e6kkan","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, University Hospital of North Norway, Troms\u00f8, Norway"},{"name":"Department of Clinical Medicine, Thrombosis Research Group (TREC), UiT \u2013 The Arctic University of Norway, Troms\u00f8, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Ghanima","sequence":"additional","affiliation":[{"name":"Department of Research, \u00d8stfold Hospital, Sarpsborg, Norway"},{"name":"Clinic of Internal Medicine, \u00d8stfold Hospital, Sarpsborg, Norway"},{"name":"Department of Hematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazdak","family":"Tavoly","sequence":"additional","affiliation":[{"name":"Department of Research, \u00d8stfold Hospital, Sarpsborg, Norway"},{"name":"Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"issue":"14","key":"ref1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"25","key":"ref2","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"H T S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"A A Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"S 01","key":"ref4","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.thromres.2018.01.028","article-title":"Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer","volume":"164","author":"G H Lyman","year":"2018","journal-title":"Thromb Res"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"e12653","DOI":"10.1002\/rth2.12653","article-title":"Cancer-associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study","volume":"6","author":"S Sharman Moser","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","article-title":"Cancer and venous thromboembolism","volume":"6","author":"P Prandoni","year":"2005","journal-title":"Lancet Oncol"},{"issue":"17","key":"ref8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"R D McBane II","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"20","key":"ref10","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref14","first-page":"1181","article-title":"Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"M B Streiff","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"A A Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 International Clinical Practice Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"E12770","DOI":"10.1002\/rth2.12770","article-title":"The venous thrombosis registry in \u00d8stfold Hospital (TROLL registry) - design and cohort description","volume":"6","author":"C T J\u00f8rgensen","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.33963\/KP.15042","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and colorectal cancer: a single\u2013center experience","volume":"77","author":"K St\u0119pie\u0144","year":"2019","journal-title":"Kardiol Pol"},{"issue":"S 01","key":"ref21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2021-147748","article-title":"Anticoagulant treatment patterns and outcomes in patients with venous thromboembolism and active cancer - a nationwide cohort study in France","volume":"138","author":"L Bertoletti","year":"2021","journal-title":"Blood"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1078155217730129","article-title":"Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants","volume":"25","author":"E M Uppuluri","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1055\/a-1886-5991","article-title":"Treatment and bleeding complications of cancer-associated venous thromboembolism: a Korean population-based study","volume":"122","author":"S-A Kim","year":"2022","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/1078155218757856","article-title":"A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - a real world experience","volume":"25","author":"M K Phelps","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"J I Weitz","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"106567","DOI":"10.1016\/j.vph.2019.106567","article-title":"Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study","volume":"120","author":"K Stepien","year":"2019","journal-title":"Vascul Pharmacol"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jth.15599","article-title":"Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: a systematic review","volume":"20","author":"F Moik","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1253\/circj.CJ-17-1128","article-title":"Anticoagulation therapy for venous thromboembolism in the real world-from the COMMAND VTE Registry","volume":"82","author":"Y Yamashita","year":"2018","journal-title":"Circ J"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2016.12.016","article-title":"Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis","volume":"150","author":"J A Ross","year":"2017","journal-title":"Thromb Res"},{"issue":"09","key":"ref30","first-page":"100392","article-title":"One-year incidences of venous thromboembolism, bleeding, and death in patients with lung cancer (Cancer-VTE Subanalysis)","volume":"3","author":"N Awano","year":"2022","journal-title":"JTO Clin Res Rep"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1782219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T08:12:50Z","timestamp":1730794370000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1782219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":30,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1782219","archive":["Portico","CLOCKSS"],"relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s11239-026-03270-y","asserted-by":"object"}]},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}